Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unm...
Task 3.4
Development of small peptide tracers for imaging PD-1 and PD-L1...
Description
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- Roche (Switzerland)Switzerlandhttp://www.roche.ch/en/index.htm
- Janssen (Belgium)Belgiumhttps://www.janssen.com/belgium/
- Amsterdam UMC Location Vrije Universiteit Amsterdam (VUMC)Netherlands (the)https://vumc.nl
- Takeda (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.takedacam.com/
Additional organisations
- Antaros Medical (Sweden)Swedenhttps://antarosmedical.com/
- Bayer (Germany)Germanyhttp://www.gesundheit.bayer.de/de/index.php
- Vall d'Hebron Institut de Recerca (VHIR; VHIR-CERCA)Spainhttps://vhir.vallhebron.com
- Vall d'Hebron Institute of Oncology (VHIO; VHIO-CERCA)Spainhttps://www.vhio.net
Data originator, Data holder, Data provider
- ImaginAb (United States)United States of America (the)https://www.imaginab.com/
- Pfizer (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.pfizer.co.uk/
- LygatureNetherlands (the)https://www.lygature.org/
- University of CambridgeUnited Kingdom of Great Britain and Northern Ireland (the)https://www.cam.ac.uk
Networks
Part of networks...